Literature DB >> 25824227

Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

L Davies Forsman1, C G Giske2, J Bruchfeld3, T Schön4, P Juréen5, K Ängeby6.   

Abstract

We investigated the activity of meropenem-clavulanic acid (MEM-CLA) against 68 Mycobacterium tuberculosis isolates. We included predominantly multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) isolates, since the activity of MEM-CLA for resistant isolates has previously not been studied extensively. Using Middlebrook 7H10 medium, all but four isolates showed an MIC distribution of 0.125 to 2 mg/liter for MEM-CLA, below the non-species-related breakpoint for MEM of 2 mg/liter defined by EUCAST. MEM-CLA is a potential treatment option for MDR/XDR-TB.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25824227      PMCID： PMC4432126          DOI： 10.1128/AAC.00171-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

1.  Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis.

Authors:  P R Donald; F A Sirgel; A Venter; D P Parkin; B W Van de Wal; A Barendse; E Smit; D Carman; J Talent; J Maritz
Journal:  Scand J Infect Dis       Date:  2001

2.  Further observations on penicillin. 1941.

Authors:  E P Abraham; E Chain; C M Fletcher; H W Florey; A D Gardner; N G Heatley; M A Jennings
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin.

Authors:  M Casal; F Rodriguez; M Benavente; M Luna
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

4.  The 7H11 medium for the cultivation of mycobacteria.

Authors:  M L Cohn; R F Waggoner; J K McClatchy
Journal:  Am Rev Respir Dis       Date:  1968-08

5.  Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis.

Authors:  T B Sorg; M H Cynamon
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

6.  The disposition and metabolism of meropenem in laboratory animals and man.

Authors:  M P Harrison; S R Moss; A Featherstone; A G Fowkes; A M Sanders; D E Case
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

7.  The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.

Authors:  Irem Dinçer; Alper Ergin; Tanil Kocagöz
Journal:  Int J Antimicrob Agents       Date:  2004-04       Impact factor: 5.283

8.  beta-Lactamase inhibitors and the inducibility of the beta-lactamase of Mycobacterium tuberculosis.

Authors:  Y Zhang; V A Steingrube; R J Wallace
Journal:  Am Rev Respir Dis       Date:  1992-03

9.  In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

10.  Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.

Authors:  J P Nadler; J Berger; J A Nord; R Cofsky; M Saxena
Journal:  Chest       Date:  1991-04       Impact factor: 9.410
View more
  5 in total

1.  Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors:  Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

2.  Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

Authors:  Sander P van Rijn; Marlanka A Zuur; Richard Anthony; Bob Wilffert; Richard van Altena; Onno W Akkerman; Wiel C M de Lange; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Phosphate Promotes the Recovery of Mycobacterium tuberculosis β-Lactamase from Clavulanic Acid Inhibition.

Authors:  Wouter Elings; Raffaella Tassoni; Steven A van der Schoot; Wendy Luu; Josef P Kynast; Lin Dai; Anneloes J Blok; Monika Timmer; Bogdan I Florea; Navraj S Pannu; Marcellus Ubbink
Journal:  Biochemistry       Date:  2017-11-14       Impact factor: 3.162

4.  A patient with central nervous system tuberculomas and a history of disseminated multi-drug-resistant tuberculosis.

Authors:  Samantha R Kaplan; Jeffrey Topal; Lynn Sosa; Maricar Malinis; Anita Huttner; Ajay Malhotra; Gerald Friedland
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-12-06

Review 5.  Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.

Authors:  Derek J Sloan; Joseph M Lewis
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-03       Impact factor: 2.184
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.